Citigroup
LRMR icon

Citigroup’s Larimar Therapeutics LRMR Stock Holding History

Citigroup’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-25,000
Closed -$96.8K – 5795
2024
Q4 		$96.8K Buy
+25,000
New +$165K ﹤0.01% 4854

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Citigroup's LRMR Position: Q2 2026 in Review

Citigroup reduced its Larimar Therapeutics (LRMR) stake by 1.3% in Q2 2026, selling an estimated $1.87K and leaving 35,636 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #4637.

Citigroup first reported a position in LRMR in Q3 2014 and has held it in 40 quarters since. The position peaked at $553K in Q3 2015. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Citigroup held 35,636 shares of Larimar Therapeutics worth $109K as of Q2 2026.
  • Citigroup sold 471 Larimar Therapeutics shares in Q2 2026, an estimated $1.87K.
  • Larimar Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4637 holding.
  • Citigroup first reported a position in Larimar Therapeutics in Q3 2014 and has held it in 40 quarters since.
  • Citigroup's Larimar Therapeutics position peaked at $553K in Q3 2015.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.